A biotechnology company focused on therapies that address blood clotting disorders and complications from anticoagulant drugs. Its portfolio included Andexxa, an FDA‑approved reversal agent for certain factor Xa inhibitors, and Bevyxxa, an anticoagulant designed to prevent venous thromboembolism in ...
3 members of Congress have disclosed 4 trades in Portola Pharmaceuticals, Inc. (PTLA), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 2 sales. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2019-01-02 | Lamar Smith | buy | $1K – $15K |
| 2017-01-30 | JAMES B. RENACCI | buy | $1K – $15K |
| 2016-06-10 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2015-12-21 | MICHAEL T. MCCAUL | sell | $1K – $15K |